Biosimilars 2021 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
JANUARY 11, 2022
The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g., 19 at 1–4.) 1:19-cv-01873 N.D. 3d 811 (N.D.
52 
Let's personalize your content